Berlin, Germany and Seattle, WA. U.S.A. -- Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 2,671,088 new shares that were issued in an increase of the share capital against contribution in cash and without subscription rights that was decided upon yesterday by its Executive and Supervisory Boards. A 100% subsidiary of BB MEDTECH AG (Schaffhausen, Switzerland) and funds managed by Abingworth LLP (London, UK) subscribed for all the new shares.
